Avalon Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Avalon Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,796	Closed	-$2.3M	–	138
2024 Q3	$2.3M	Buy	+15,796	New	+$2.29M	0.7%	33
2021 Q3	–	Sell	-23,838	Closed	-$3.9M	–	48
2021 Q2	$3.9M	Buy	+23,838	New	+$3.67M	3.29%	14
2017 Q2	–	Sell	-21,021	Closed	-$2.06M	–	86
2017 Q1	$2.06M	Buy	+21,021	New	+$2.01M	1.42%	23
2016 Q2	–	Sell	-10,782	Closed	-$937K	–	87
2016 Q1	$937K	Buy	10,782 +2,049	+23%	+$183K	0.75%	38
2015 Q4	$985K	Buy	+8,733	New	+$948K	0.89%	42
2014 Q3	–	Sell	-13,710	Closed	-$1.18M	–	84
2014 Q2	$1.18M	Buy	+13,710	New	+$1.08M	0.98%	34
2013 Q4	–	Sell	-5,292	Closed	-$370K	–	112
2013 Q3	$370K	Buy	+5,292	New	+$347K	0.37%	70

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Avalon Capital Management's IBB Position: Q4 2024 in Review

Avalon Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2024, closing a stake of 15,796 shares — an estimated $2.3M sold.

Avalon Capital Management first reported a position in IBB in Q3 2013 and held it in 7 quarters. The position peaked at $3.9M in Q2 2021. 875 funds tracked by Wall St. Rank hold IBB as of Q4 2024.

Avalon Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
Avalon Capital Management sold 15,796 iShares Biotechnology ETF shares in Q4 2024, an estimated $2.3M.
Avalon Capital Management first reported a position in iShares Biotechnology ETF in Q3 2013 and held it in 7 quarters.
Avalon Capital Management's iShares Biotechnology ETF position peaked at $3.9M in Q2 2021.
875 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2024.

Based on Avalon Capital Management's 13F filing for Q4 2024, filed 4 Feb 2025.